Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.